Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). “This was a safety-related labeling change for the glucagon-like peptide 1 receptor ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

When a drug is officially in shortage, the FDA allows compounders to make copies. That has been the case for these medications. But Novo Nordisk and Eli Lilly and Company, which makes tirzepatide ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...